Russell Investments Group Ltd. Purchases 23,736 Shares of DaVita Inc. $DVA

Key Points

• Russell Investments Group Ltd. increased its stake in DaVita Inc. by 73.0% during the first quarter, acquiring an additional 23,736 shares, raising its total to 56,248 shares valued at approximately $8.5 million.
• Recent analyst reports have shifted DaVita's rating from "hold" to "buy," with a consensus target price of $164.00, reflecting optimism about the company's financial outlook.
• DaVita reported earnings of $2.95 per share for the latest quarter, surpassing estimates and showing a revenue increase of 6.1% year-over-year, leading to revised guidance for the fiscal year.

Russell Investments Group Ltd. lifted its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 73.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 56,248 shares of the company's stock after purchasing an additional 23,736 shares during the quarter. Russell Investments Group Ltd. owned about 0.07% of DaVita worth $8,529,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of DVA. UMB Bank n.a. grew its position in shares of DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after purchasing an additional 76 shares during the period. Copia Wealth Management acquired a new position in shares of DaVita in the 4th quarter valued at approximately $30,000. Y.D. More Investments Ltd acquired a new position in shares of DaVita in the 1st quarter valued at approximately $35,000. Coppell Advisory Solutions LLC grew its position in shares of DaVita by 50.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after purchasing an additional 100 shares during the period. Finally, GeoWealth Management LLC boosted its position in DaVita by 30.6% during the 4th quarter. GeoWealth Management LLC now owns 525 shares of the company's stock worth $79,000 after acquiring an additional 123 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider James O. Hearty sold 2,351 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total value of $352,650.00. Following the sale, the insider owned 26,038 shares in the company, valued at approximately $3,905,700. This represents a 8.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.50% of the company's stock.

DaVita Stock Up 2.0%

Shares of NYSE:DVA traded up $2.7250 during midday trading on Friday, hitting $140.3050. The stock had a trading volume of 714,621 shares, compared to its average volume of 854,957. DaVita Inc. has a 12 month low of $126.07 and a 12 month high of $179.60. The company has a quick ratio of 1.34, a current ratio of 1.39 and a debt-to-equity ratio of 23.18. The business's 50-day simple moving average is $139.63 and its 200-day simple moving average is $143.90. The company has a market cap of $10.03 billion, a P/E ratio of 13.80, a PEG ratio of 1.01 and a beta of 1.09.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business had revenue of $3.38 billion during the quarter, compared to analysts' expectations of $3.36 billion. During the same period last year, the business earned $2.00 earnings per share. The firm's revenue was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, sell-side analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

DVA has been the subject of a number of recent research reports. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research report on Friday. Truist Financial set a $148.00 price target on DaVita in a research report on Friday, August 8th. Finally, Barclays reduced their price target on DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, DaVita currently has a consensus rating of "Hold" and an average target price of $164.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.